E-DRUG: What are potential problems with FDCs? (3)
---------------------------------------------------
Dear Chris:
The differences in the situation you cite has all to do with the release
rate characteristics and the bioavailability, of the drugs from the
combination products vs. from the three individual products.
Which is a better therapy from a bioavailability perspective depends on the
drug formulations in question, and the data made available by the
manufacturers.
From a patient compliance perspective taking one tablet vs. taking three -
the single combo product wins (hands down!).
I hope this helps,
Michael Anisfeld
------------------------------------
Globepharm
Anisfeld, Michael
President
manisfeld@globepharm.org
313 Pine Street (Ste 104)
Deerfield IL 60015, USA
tel: 1 847 914 0922
fax: 1 847 914 0988
mobile: 1 224 619 5939
www.globepharm.org
--
To send a message to E-Drug, write to: e-drug@healthnet.org
To subscribe or unsubscribe, write to: majordomo@healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: e-drug-help@healthnet.org
Information and archives: Essentialdrugs.org